iPharmaCenter

  • LinkedIn Social Icon
  • Twitter Social Icon

Putting patients at center

  • Home

  • COVID-19

  • News

  • Conferences

  • Healthcare Policies & Systems

  • Regional News

    • North America
    • Europe
    • APAC
  • Patient info

  • More

    Use tab to navigate through the menu items.
    • All Posts
    • TraditionalHealthcare
    • Healthcare Systems
    • News
    • Conferences
    • Know your disease
    • COVID
    • Japan drug approvals
    • USA Pharma News | Healthcare News
    • Europe Pharma News
    • Japan drug approvals
    • Australia Pharma & Healthcare News
    • Canada Pharma and Healthcare News
    • Asia | Pharma | Healthcare News
    • Indication News
    Search
    European Academy of Neurology (EAN) Congress 2022 | News | Updates | iPharmaCenter
    ipharmaservices
    • 9 hours ago

    European Academy of Neurology (EAN) Congress 2022 | News | Updates | iPharmaCenter

    NOVARTIS - KESIMPTA NOVARTIS PRESENTED STRONG EXTENSION STUDY DATA OF KESIMPTA AT THE EAN 2022 CONGRESS Novartis announced new data from...
    0
    BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter
    ipharmaservices
    • 3 days ago

    BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

    Bristol Myers Squibb announced that Breyanzi (lisocabtagene maraleucel) was approved by the U.S. Food and Drug Administration (FDA) for...
    0
    1
    2345

    Please feel free to share your thoughts and comments. If you have questions, please comment, and we will try to get back with answers. If you liked the content, please share it on your network.

    For any further updates, contact us at ipharmaservices@gmail.com

    ©2022 by ipharmaservices